Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top ...

The Marketing Association of Pakistan (MAP) has announced its newly elected office bearers and Council members. Muhammad ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

US health insurance giant UnitedHealth Group has appointed company veteran Tim Noel as chief executive of UnitedHealthcare, ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...

Appasamy Associates has appointed Annaswamy Vaidheesh as its non-executive chairman. With over 35 years of experience in the ...

Chugai Pharm signs collaboration agreement with GSK's Global Health Unit for development of anti-dengue virus antibody: Tokyo Friday, January 31, 2025, 09:00 Hrs [IST] Chugai Phar ...

Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based ...